Research and Markets (http://www.researchandmarkets.com/research/a9fb21/venezuela_pharmace) has announced the addition of the "Venezuela Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
Venezuela Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Venezuela's pharmaceuticals and healthcare industry.
Despite a challenging operating environment, Venezuela’s pharmaceutical market remains on multinational drugmakers’ radars on account of its size. Estimates that the drug market (over-the-counter and prescription) is worth VEB4.6bn (US$2.1bn). Over the forecast period, we expect substantial growth in pharmaceutical consumption to drive the market, despite price controls on many medicines holding down price growth in the face of strong consumer price inflation. By 2012, we expect drug market expenditure to have reached VEB11.4bn (US$3.3bn), representing average year-on-year (y-o-y) growth of 20% in local currency terms. A depreciating currency means that in US dollar terms, growth will be much slower, averaging 9% y-o-y.
In updated Business Environment Rankings for Q308, Venezuela remains in second to last position. Its large market and country structure means that strong returns from the market are possible. However, Venezuela has the riskiest regulatory environment in the region on account of its weak intellectual property protections and strict policy on pharmaceutical pricing.
Key Topics Covered:
Executive Summary
Venezuela Pharmaceuticals And Healthcare Industry SWOT Analysis
Venezuela Political SWOT Analysis
Venezuela Economic SWOT Analysis
Venezuela Business Environment SWOT Analysis
Pharmaceutical Business Environment Ratings
Table: Americas Pharmaceutical Business Environment Rankings
Limits Of Potential Returns
Risks To Realisation Of Returns
Venezuela – Market Summary
Regulatory Regime
Intellectual Property Environment
Pricing And Reimbursement
Other Regulatory Issues
Industry Developments
Healthcare Sector
Epidemiology
Pharmaceutical Sector Developments
Company Activity
Pharmacy Sector
Industry Forecast Scenario
Overall Market Forecast
Table: Venezuela Drug Market Trends
Key Growth Factors – Industry
Table: Venezuela Health Expenditure Trends
Key Growth Factors – Macroeconomic
Table: Venezuela Economic Activity
OTC Market Forecast
Table: Venezuela’s OTC Market Indicators (US$mn unless otherwise stated)
Prescription Drug Market Forecast
Table: Venezuela Prescription Market Indicators (US$mn)
Generics Market Forecast
Table: Venezuela Generics Market Indicators
Import/Export Forecasts
Table: Venezuela Import/Export Forecast
Other Healthcare Data Forecasts
Table: Venezuela Pharmaceuticals And Healthcare Sector
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Company Profiles
Leading Multinationals
Sanofi-Aventis
Pfizer
Merck & Co
Novartis
GlaxoSmithKline
Boehringer Inglelheim
Indigenous Company Profiles
Elmor
Grupo Farma
Calox International
Strides Latina (Sumifarma)
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Companies Mentioned:
- Sanofi-Aventis
- Pfizer
- Merck & Co
- Novartis
- GlaxoSmithKline
- Boehringer Inglelheim
- Elmor
- Grupo Farma
- Calox International
- Strides Latina (Sumifarma)
For more information visit http://www.researchandmarkets.com/research/a9fb21/venezuela_pharmace
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax
from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
